GORDIAN PHARMA LIMITED
Research and experimental development on biotechnology
GORDIAN PHARMA LIMITED
Research and experimental development on biotechnology
Contact & Details
Contact
Registered Address
Aberllech Pentre Bach Brecon LD3 8UB Wales
Full company profile for GORDIAN PHARMA LIMITED (12411459), an active life sciences and medical technology company based in Brecon, Wales. Incorporated 20 Jan 2020. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.
Business Summary
This company specializes in providing innovative solutions and services across multiple sectors. Sign up to viewReports
Credit Report
In-depth credit score, financial analysis, risk assessment and company intelligence.
Financials
Financials
Net Assets, Total Assets & Total Liabilities (2020–2024)
Cash in Bank
£239.69k
Net Assets
£66.89k
Total Liabilities
£222.74k
Turnover
N/A
Employees
4
Debt Ratio
77%
Financial History
Revenue, profit, EBITDA and key financial figures
2024 Dec Year End | 2023 Dec Year End | |
|---|---|---|
| P&L | ||
| Revenue | ||
| Gross Profit | ||
| Operating Profit | ||
| Net Profit | ||
| EBITDA | ||
| Assets | ||
| Cash | ||
| Total Assets | ||
| Liabilities | ||
| Total Liabilities | ||
| Key Metrics | ||
| Employees | ||
Funding
Fundraising & Grants
No fundraising or grants recorded
Investors (0)
No investor information available
Officers
Officers
| Status | |||||
|---|---|---|---|---|---|
| Beatson-hird, Jonathan Denis | Director | British | Wales | 20 Jan 2020 | Active |
| Wyllie, Michael Grant, Dr | Director | British | United Kingdom | 20 Jan 2020 | Active |
See all 7 officers
Sign up to view the full officer history
Persons with Significant Control
Persons with Significant Control (1)
Morvus Technology Limited
United Kingdom
- Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent
Group Structure
Group Structure
Charges
Charges
No charges registered
Properties
Properties
No related properties
Documents
Company Filings
| Date | Category | Description | Document |
|---|---|---|---|
| 11 Apr 2026 | Resolution | Resolutions | |
| 27 Feb 2026 | Miscellaneous | Replacement filing of SH01 - 26/11/25 Statement of Capital gbp 2175.625197 | |
| 27 Feb 2026 | Confirmation Statement | Confirmation statement made on 2026-01-14 with updates | |
| 26 Jan 2026 | Officers | Appointment of Dr Michael John Peagram as director on 2025-11-26 | |
| 26 Jan 2026 | Capital | Allotment of shares (GBP 2,175.62553) on 2025-11-26 |
Resolutions
Replacement filing of SH01 - 26/11/25 Statement of Capital gbp 2175.625197
Confirmation statement made on 2026-01-14 with updates
Appointment of Dr Michael John Peagram as director on 2025-11-26
Allotment of shares (GBP 2,175.62553) on 2025-11-26
Recent Activity
Latest Activity
Resolutions
1 weeks ago on 11 Apr 2026
Replacement filing of SH01 - 26/11/25 Statement of Capital gbp 2175.625197
1 months ago on 27 Feb 2026
Confirmation statement made on 2026-01-14 with updates
1 months ago on 27 Feb 2026
Appointment of Dr Michael John Peagram as director on 2025-11-26
2 months ago on 26 Jan 2026
Allotment of shares (GBP 2,175.62553) on 2025-11-26
2 months ago on 26 Jan 2026